Business Wire

Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...
News Medical

FDA approves first generic glucagon for injection to treat severe hypoglycemia

Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low blood ...
Business Wire

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged ...

CHICAGO & DUBLIN--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...
The New England Journal of Medicine

Glucagon Treatment of Insulin Reactions

Eighteen hospitalized male diabetic patients, thirty to sixty-nine years of age, were studied. The known duration of the diabetes in the group ranged from one to twenty-five years. All patients ...
Medscape

Intranasal Glucagon Promising for Severe Hypoglycemia

STOCKHOLM — New data on a needle-free nasal delivery system for glucagon for use in severe hypoglycemia presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting here today ...